ML22161A975

Shine Technologies, LLC - Application for an Operating License Supplement No. 23

ML22161A975
Person / Time
Site:	SHINE Medical Technologies
Issue date:	06/10/2022
From:	Jim Costedio SHINE Medical Technologies
To:	Document Control Desk, Office of Nuclear Reactor Regulation
Shared Package
ML22161A974	List: ML22161A975 ML22161A977 ML22161A978
References
2022-SMT-0065
Download: ML22161A975 (2)

Text

THIS LETTER CONTAINS PROPRIETARY AND EXPORT CONTROLLED INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 June 10, 2022 2022-SMT-0065 10 CFR 50.30 U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555

References:

(1) SHINE Medical Technologies, LLC letter to the NRC, SHINE Medical Technologies, LLC Application for an Operating License, dated July 17, 2019 (ML19211C143)

SHINE Technologies, LLC Application for an Operating License Supplement No. 23 Pursuant to 10 CFR Part 50.30, SHINE Technologies, LLC (SHINE) submitted an application for an operating license for a medical isotope production facility to be located in Janesville, Wisconsin (Reference 1). SHINE has determined that a supplement to the operating license application is necessary to address open technical items discussed with the NRC staff during regulatory audits and to address facility design changes.

This submittal contains information which SHINE requests to be withheld from public disclosure, including proprietary information in accordance with 10 CFR 2.390(a)(4) and export controlled information (ECI) in accordance with 10 CFR 2.390(a)(3). provides the non-public version of the SHINE Final Safety Analysis Report (FSAR)

Change Summary, including a mark-up of affected FSAR pages not previously submitted. contains proprietary information, a subset of which has been determined to be ECI.

SHINE requests that the NRC withhold Enclosure 1 from public disclosure under 10 CFR 2.390. provides the public version of the SHINE FSAR Change Summary. provides an affidavit supporting the proprietary treatment of the SHINE proprietary information contained in Enclosure 1, pursuant to 10 CFR 2.390. SHINE requests that the NRC withhold Enclosure 1 from public disclosure under 10 CFR 2.390. Upon removal of Enclosure 1, this letter is uncontrolled.

If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.

3400 Innovation Ct.

• Janesville, WI 53546

• 877.512.6554

• info@shinemed.com

• www.SHINEtechnologies.com




     

Document Control Desk Page 2 I declare under the penalty of perjury that the foregoing is true and correct.

Executed on June 10, 2022.

Very truly yours, James Costedio Vice President of Regulatory Affairs and Quality SHINE Technologies, LLC Docket No. 50-608 Enclosures cc: Project Manager, USNRC SHINE General Counsel Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health (w/o Enclosure 1)